Table 1.

Approved combination in the clinic

Cancer	Immune checkpoint inhibitor	Anti-angiogenic agents	Study name	Clinical trial number	Reference
RCC	Atezolizumab	Bevacizumab	IMmotion151	NCT02420821	Rini, B et al. Lancet 2019 [40, 41]
RCC	Avelumab	Axitinib	JAVELIN Renal 101	NCT02684006	Motzer, RJ et al. NEJM 2019 [38]
RCC	Pembrolizumab	Axitinib	KEYNOTE-426	NCT02853331	Rini, B et al. NEJM 2019 [40, 41]
RCC	Nivolumab	Cabozantinib	CheckMate 9ER	NCT03141177	Choueri, TK et al. NEJM 2021 [42]
RCC	Pembrolizumab	Lenvatinib	CLEAR	NCT02811861	Motzer, RJ et al. NEJM 2021 [37]
HCC	Atezolizumab	Bevacizumab	IMbrave150	NCT03634540	Makker V et al. NEJM 2022 [45]
EC	Pembrolizumab	Lenvatinib	Study 309–KEYNOTE-775	NCT03517449	Finn RS et al. NEJM 2020 [43]